Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases

Cyclin-dependent kinase 9 (Cdk9) is a cdc2-like serine/threonine kinase. The so-called Cdk9-related pathway comprises two Cdk9 isoforms (Cdk9-42 and Cdk9-55), cyclin T1, cyclin T2a, cyclin T2b and cyclin K. The association between Cdk9 and one of its cyclin partners forms a heterodimer, which is the main component of the positive transcription elongation factor (P-TEFb). The latter stabilizes the elongation process of RNA polymerase II (polII) transcripts. Through the control of RNA polII-mediated gene expression, the Cdk9-related pathway performs an important role in several biological processes, such as cell growth, proliferation, protection from apoptosis and differentiation. Incidentally, the P-TEFb that contains the heterodimer Cdk9-cyclin T1 is also critical for HIV-1 and HIV-2 replication in human cells. A deregulation in the Cdk9-related pathway is associated with various types of human malignancies and cardiomyocytes hypertrophy. On these grounds, the characterization of Cdk9-related pathway deregulation might have a two-fold purpose: (1) the development of novel kinase inhibitors for the treatment of cancer, AIDS and cardiac hypertrophy and (2) a better understanding of the pathogenesis and progression of these maladies.

[1]  A. Musarò,et al.  Cdk9‐55: A new player in muscle regeneration , 2008, Journal of cellular physiology.

[2]  Peter M Fischer,et al.  Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. , 2008, Trends in pharmacological sciences.

[3]  A. Giordano,et al.  Cdk9/Cyclin T1 complex: A key player during the activation/differentiation process of normal lymphoid B cells , 2008, Journal of cellular physiology.

[4]  K. Knudsen,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas AR, the cell cycle, and prostate cancer , 2022 .

[5]  A. Giordano,et al.  From G0 to S phase: A view of the roles played by the retinoblastoma (Rb) family members in the Rb‐E2F pathway , 2007, Journal of cellular biochemistry.

[6]  A. Giordano,et al.  Tumor suppressor pRb2/p130 gene and its derived product Spa310 spacer domain as perspective candidates for cancer therapy , 2007, Journal of cellular physiology.

[7]  G. Romano Advances in the field of stem cell research. , 2007, Drug news & perspectives.

[8]  L. Meijer,et al.  Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. , 2007, Cancer research.

[9]  S. Pikkarainen,et al.  Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses , 2007, Journal of cellular physiology.

[10]  A. Giordano,et al.  The role of the Cdk9/Cyclin T1 complex in T cell differentiation , 2007, Journal of cellular physiology.

[11]  A. Giordano,et al.  Carcinogenesis and environment: the cancer stem cell hypothesis and implications for the development of novel therapeutics and diagnostics. , 2007, Frontiers in bioscience : a journal and virtual library.

[12]  Danish Sayed,et al.  MicroRNAs Play an Essential Role in the Development of Cardiac Hypertrophy , 2007, Circulation research.

[13]  J. Ladias,et al.  Crystal structure of human cyclin K, a positive regulator of cyclin-dependent kinase 9. , 2007, Journal of molecular biology.

[14]  M. Barbacid,et al.  Cell cycle kinases in cancer. , 2007, Current opinion in genetics & development.

[15]  P. Dirks,et al.  Cancer stem cells: at the headwaters of tumor development. , 2007, Annual review of pathology.

[16]  G. Romano Perspectives and controversies in the field of stem cell research. , 2006, Drug news & perspectives.

[17]  A. Giordano,et al.  Cdk9 phosphorylates p53 on serine 392 independently of CKII , 2006, Journal of cellular physiology.

[18]  A. Giordano,et al.  RB and cell cycle progression , 2006, Oncogene.

[19]  K. Kristiansen,et al.  Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. , 2006, Molecular endocrinology.

[20]  J. Brady,et al.  Tax Interacts with P-TEFb in a Novel Manner To Stimulate Human T-Lymphotropic Virus Type 1 Transcription , 2006, Journal of Virology.

[21]  M. West,et al.  EBV EBNA 2 stimulates CDK9-dependent transcription and RNA polymerase II phosphorylation on serine 5 , 2006, Oncogene.

[22]  A. Gartel,et al.  CDK9 Phosphorylates p53 on Serine Residues 33, 315 and 392 , 2006, Cell cycle.

[23]  A. Giordano,et al.  MyoD recruits the cdk9/cyclin T2 complex on Myogenic‐genes regulatory regions , 2006, Journal of cellular physiology.

[24]  H. Zhen,et al.  Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas , 2005, Cancer.

[25]  X. Graña,et al.  Cyclin T1 Expression Is Regulated by Multiple Signaling Pathways and Mechanisms during Activation of Human Peripheral Blood Lymphocytes1 , 2005, The Journal of Immunology.

[26]  M. Barbacid,et al.  Mammalian cyclin-dependent kinases. , 2005, Trends in biochemical sciences.

[27]  G. Romano The role of adult stem cells in carcinogenesis. , 2005, Drug news & perspectives.

[28]  N. Pedersen,et al.  Analysis of the epidermal growth factor receptor specific transcriptome: Effect of receptor expression level and an activating mutation , 2005, Journal of cellular biochemistry.

[29]  W. Plunkett,et al.  Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. , 2005, Blood.

[30]  P. Dent,et al.  Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms. , 2005, Gene.

[31]  C. H. Herrmann,et al.  Differential localization and expression of the Cdk9 42k and 55k isoforms , 2005, Journal of cellular physiology.

[32]  A. Giordano,et al.  Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors , 2005, Cancer biology & therapy.

[33]  Michael S Lauer,et al.  Left ventricular hypertrophy: the next treatable, silent killer? , 2004, JAMA.

[34]  S. Pileri,et al.  CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation , 2004, The Journal of pathology.

[35]  J. Borst,et al.  CD27 Is Acquired by Primed B Cells at the Centroblast Stage and Promotes Germinal Center Formation1 , 2004, The Journal of Immunology.

[36]  Ching-Jin Chang,et al.  Autocrine/Paracrine Secreted Frizzled-related Protein 2 Induces Cellular Resistance to Apoptosis , 2004, Journal of Biological Chemistry.

[37]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[38]  C. Cinti,et al.  How does a normal human cell become a cancer cell? , 2003, Journal of experimental & clinical cancer research : CR.

[39]  G. Romano Gene transfer in experimental medicine. , 2003, Drug news & perspectives.

[40]  D. Price,et al.  Identification of a novel isoform of Cdk9. , 2003, Gene.

[41]  A. Baldi,et al.  Cyclin T: Three forms for different roles in physiological and pathological functions , 2003, Journal of cellular physiology.

[42]  A. Giordano,et al.  Activation and function of cyclin T–Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy , 2002, Nature Medicine.

[43]  A. Giordano,et al.  Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines , 2002, Oncogene.

[44]  P. Stiegler,et al.  Activation of MyoD-dependent transcription by cdk9/cyclin T2 , 2002, Oncogene.

[45]  A. Giordano,et al.  Physical interaction between pRb and cdk9/cyclinT2 complex , 2002, Oncogene.

[46]  M. Siddiqui,et al.  Structure, expression, and functional characterization of the mouse CLP-1 gene. , 2002, Gene.

[47]  B. Peterlin,et al.  P-TEFb Containing Cyclin K and Cdk9 Can Activate Transcription via RNA* , 2002, The Journal of Biological Chemistry.

[48]  A. Giordano,et al.  CDK9: From Basal Transcription to Cancer and AIDS , 2002, Cancer biology & therapy.

[49]  H. Nakshatri,et al.  Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor kappaB-mediated antiapoptosis involving c-IAP2. , 2001, Blood.

[50]  P. Sharp,et al.  Positive Transcription Elongation Factor b Phosphorylates hSPT5 and RNA Polymerase II Carboxyl-terminal Domain Independently of Cyclin-dependent Kinase-activating Kinase* , 2001, The Journal of Biological Chemistry.

[51]  Chawnshang Chang,et al.  Androgen Receptor Interacts with the Positive Elongation Factor P-TEFb and Enhances the Efficiency of Transcriptional Elongation* , 2001, The Journal of Biological Chemistry.

[52]  A. Rice,et al.  Antiapoptotic Function of Cdk9 (TAK/P-TEFb) in U937 Promonocytic Cells , 2001, Journal of Virology.

[53]  J. Choe,et al.  Regulation of CD27 expression in the course of germinal center B cell differentiation: the pivotal role of IL‐10 , 2000, European journal of immunology.

[54]  A. Rice,et al.  Genomic organization and characterization of promoter function of the human CDK9 gene. , 2000, Gene.

[55]  P. Stiegler,et al.  Genomic organization, promoter analysis, and chromosomal mapping of the mouse gene encoding Cdk9 , 2000, Journal of cellular biochemistry.

[56]  J. Dyck,et al.  Identification of genes regulated during mechanical load-induced cardiac hypertrophy. , 2000, Journal of molecular and cellular cardiology.

[57]  D. Price P-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II , 2000, Molecular and Cellular Biology.

[58]  D. Chen,et al.  Requirement for a Kinase-specific Chaperone Pathway in the Production of a Cdk9/Cyclin T1 Heterodimer Responsible for P-TEFb-mediated Tat Stimulation of HIV-1 Transcription* , 2000, The Journal of Biological Chemistry.

[59]  Junmin Peng,et al.  Cyclin K Functions as a CDK9 Regulatory Subunit and Participates in RNA Polymerase II Transcription* , 1999, The Journal of Biological Chemistry.

[60]  M. Kasten,et al.  Regulatory functions of Cdk9 and of cyclin T1 in HIV Tat transactivation pathway gene expression , 1999, Journal of cellular biochemistry.

[61]  B. Calabretta,et al.  Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis , 1999, Molecular and Cellular Biology.

[62]  G. Romano,et al.  Dissociation between resistance to apoptosis and the transformed phenotype in IGF‐I receptor signaling , 1999, Journal of cellular biochemistry.

[63]  X. Graña,et al.  Upregulation of cyclin T1/CDK9 complexes during T cell activation , 1998, Oncogene.

[64]  A. Rice,et al.  Tat-Associated Kinase, TAK, Activity Is Regulated by Distinct Mechanisms in Peripheral Blood Lymphocytes and Promonocytic Cell Lines , 1998, Journal of Virology.

[65]  A. Giordano,et al.  Cloning of murine CDK9/PITALRE and its tissue‐specific expression in development , 1998, Journal of cellular physiology.

[66]  A. Giordano,et al.  The standpoint of AIDS research and therapy programs. , 1998, Anticancer research.

[67]  J. Milton,et al.  Identification of multiple cyclin subunits of human P-TEFb. , 1998, Genes & development.

[68]  A. Giordano,et al.  PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[69]  P. Luciw,et al.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product , 1987, Nature.

[70]  James R Bischoff,et al.  CDK inhibitors in cancer therapy: what is next? , 2008, Trends in pharmacological sciences.

[71]  T. Cheng,et al.  The CDK inhibitors: potential targets for therapeutic stem cell manipulations? , 2008, Gene Therapy.

[72]  A. Giordano,et al.  Abrogation of signal-dependent activation of the cdk9/cyclin T2a complex in human RD rhabdomyosarcoma cells , 2007, Cell Death and Differentiation.

[73]  Hilmar Weinmann,et al.  Drug discovery process for kinase inhibitors. , 2005, Chembiochem : a European journal of chemical biology.

[74]  Yusuke Nakamura,et al.  Cyclin K as a direct transcriptional target of the p53 tumor suppressor. , 2002, Neoplasia.

[75]  A. Giordano,et al.  Distinct regions of cyclinT1 are required for binding to CDK9 and for recruitment to the HIV‐1 Tat/TAR complex , 2001, Journal of cellular biochemistry. Supplement.

[76]  A. Giordano,et al.  Transcriptional activity of P-TEFb kinase in vivo requires the C-terminal domain of RNA polymerase II. , 2000 .

[77]  G. Romano,et al.  Insulin and IGF-I Receptors Signaling in Protection from Apoptosis , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.